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REPORT FROM THE COMMISSION 
on the assessment of the functioning of Council Decision 2005/387/JHA on the 
information exchange, risk assessment and control of new psychoactive substances 
1. INTRODUCTION 
New psychoactive substances1 are becoming widely available at an unprecedented pace. The 
speed at which they appear and the way they can be distributed challenge the established 
procedures for monitoring, responding to and controlling the use of new psychoactive 
substances, according to a 2010 report of Europol and the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA).2  
Council Decision 2005/387/JHA on the information exchange, risk assessment and control of 
new psychoactive substances adopted on 10 May 20053 (‘the Council Decision’) sets up an 
EU-wide system for dealing with these new narcotic drugs and psychotropic substances 
entering the European market. It involves the exchange of information (early warning system) 
between Member States on such substances, their risk assessment and, if necessary, their 
submission to control measures and criminal sanctions4 across the EU.  
The present assessment is a follow-up to the recommendation of the EU Drugs Action Plan 
2009-2012,5 which requires the Commission to ‘assess the functioning’ of this Council 
Decision ‘and amend it, if necessary’. The Commission has done this with the support of 
EMCDDA, its Scientific Committee and Europol. Member States provided input through a 
survey (‘the Survey’)6. 
The assessment highlights the fact that the market for new psychoactive substances has 
changed dramatically in the past three years: there has been a significant increase in the 
number of substances detected, their variety and the diversification of their distribution 
                                                 
1 Under the definitions of the Council Decision (Article 3), ‘new psychoactive substance’ means a new 
narcotic drug or a new psychotropic drug in pure form or in a preparation; ‘new narcotic drug’ means a 
substance, in pure form or in a preparation, that has not been scheduled under the 1961 United Nations 
Single Convention on Narcotic Drugs, and that may pose a threat to public health comparable to the 
substances listed in Schedules I, II or IV; ‘new psychotropic drug’ means a substance in pure form or in 
a preparation that has not been scheduled under the 1971 United Nations Convention on Psychotropic 
Substances, and that may pose a threat to public health comparable to the substances listed in Schedules 
I, II, III or IV. 
2 EMCDDA-Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA, 
p.15. 
3 OJ L 127, 20.5.2005, p. 32-37. 
4 Member States should take the necessary measures by virtue of their obligations under the UN 1971 
Convention on Psychotropic Substances and the 1961 UN Single Convention on Narcotic Drugs 
(Article 9 of the Council Decision). These obligations are stated under Article 3 of the 1988 UN 
Convention against illicit traffic in narcotic drugs and psychotropic substances: ‘Each Party shall adopt 
such measures as may be necessary to establish as criminal offences under its domestic law, when 
committed intentionally’ the production, manufacture, distribution, sale, delivery, transport, importation 
or exportation, the possession or purchase of any narcotic drug or any psychotropic substance. 
5 OJ C 326, 20.12.2008, p. 7–25. Action 69. 
6 See Annex (section 7) for a summary report of the findings of the survey. 
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channels. It concludes that the Council Decision is not an adequate instrument to address 
these new challenges. The Commission therefore invites the European Parliament and the 
Council to contribute to a debate on ways of reinforcing the EU legislation. This is with a 
view to possible Commission legislative proposals in 2012.  
2. NEW PSYCHOACTIVE SUBSTANCES IN THE EU: EVOLUTION AND CHALLENGES  
In the past five years, Member States have notified 115 psychoactive substances7 through the 
information exchange mechanism8 set up by the Council Decision. While in the period 2005-
2008 the number of new substances notified was stable at 10-15 a year, from 2009 there was a 
large increase in the number of notifications.  
Many new psychoactive substances are in fact variations within a specific group of chemicals 
and are similar to substances controlled at national level. Some are products containing herbal 
and synthetic compounds that appear in various mixtures in different Member States. One 
example is Spice, a mixture containing herbs and synthetic cannabinoids that mimic the 
effects of cannabis9. They are difficult to identify and regulate because of their diversity and 
the speed with which they are developed to replace those that are controlled. 
Many of these substances are manufactured in commercial laboratories, probably in Asia10, 
and are often cheaper than illicit drugs. Despite their status as licit substances (‘legal highs’)11 
— which could make users believe that they are safe — they may pose a threat to public 
health comparable with the illicit drugs listed in the so-called schedules to the United Nations 
Conventions on Narcotic Drugs and on Psychotropic Substances. Their constituent 
compounds and the effects they have are often unclear. Hence, they can be toxic, addictive 
and have long-term adverse effects. For users, the main sources of information on their 
potential effects and risks are websites and messages posted on the internet by drug user 
communities. They are marketed and sold mainly through specialised shops, illicit drug 
sellers and over the internet.  
For many years specialised shops selling new psychoactive substances existed in only a few 
Member States. In the past two years, however, such shops have opened up at a rapid pace in 
several countries, including Poland, Ireland and Romania. There is no common approach 
across the EU to the regulation of the specialised shops. Nevertheless, national decisions on 
these shops can have knock-on effects on other Member States’ policies12.  
                                                 
7 See Annex (section 4 and 7) for a breakdown of notified substances, types and trends. 
8 The EMCDDA/ Europol Early Warning System, in which all Member States participate. 
9 Spice first appeared in Europe in 2006 and gained popularity in 2008. None of the Spice compounds 
have developed as a drug in its own rights; www.emcdda.europa.eu/publications/thematic-papers/spice 
10 In particular in China and India. 
11 ‘Legal highs’ is an umbrella term for internationally unregulated psychoactive compounds or products 
containing them, specifically designed to mimic the effects of known (established) drugs, often with the 
aim of circumventing existing drug controls. The term encompasses a wide range of synthetic and 
plant-derived substances and products, including ‘research chemicals’, ‘party pills’, ‘herbal highs’, etc., 
which are usually sold via the Internet or in smart/head shops, advertised with aggressive and 
sophisticated marketing strategies, and in some cases intentionally mislabelled with purported 
ingredients differing from the actual composition. The ‘legal highs’ market is distinguished by the 
speed at which suppliers circumvent drug controls by offering new alternatives to restricted products. 
12 For instance, recent interventions by the Polish authorities on over 1,300 head shops in the country has 
resulted in traders opening similar shops in neighbouring Czech Republic. 
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The EMCDDA’s 2010 snapshot survey13 identified 136 online shops selling new 
psychoactive substances. Most of these shops were based in the Netherlands, the UK and 
Germany, but at least five were found in Poland, France and Hungary.  
The Member States have been affected by new psychoactive substances in different ways. 
They have used different laws to control or regulate the manufacture, sale and possession of 
new psychoactive substances, in particular drugs control and medicines legislation. They can 
also use legislation based on several directives and regulations14 that tackle food safety,15 
consumer protection, dangerous substances and products at EU level.16 However, some new 
psychoactive substances are sold – for example - with the label ‘not for human consumption’, 
to circumvent drugs legislation17.  
3. OBJECTIVES AND SCOPE OF THE COUNCIL DECISION 
The Council Decision of 10 May 2005 was adopted on the basis of ex-articles 29, 31(1)(e) 
and 34(2)(c)18 of the Treaty on European Union (third pillar). Its rationale was to enable 
Member States to tackle the emergence of psychoactive substances effectively by submitting 
them to EU-wide control measures.  
There are six steps in the procedure established by the Council Decision for submitting a new 
psychoactive substance to control measures: 1) a Member State provides information on a 
new substance on its market; 2) Europol and the EMCDDA, in collaboration with the 
European Medicines Agency (EMA) prepare a Joint Report and submit it to the Council; 3) 
the Council requests a Risk Assessment from the EMCDDA; 4) the EMCDDA submits the 
risk assessment to the Council and the Commission; 5) the Commission presents an initiative 
for control measures to the Council; 6) the Council decides on the submission of the substance 
to control measures and on the obligation to introduce criminal law measures. This procedure 
has been used only twice since 2005. In 2007 the Council decided to submit BZP19 to control 
measures and in 2010 it submitted mephedrone.20  
                                                 
13 EMCDDA, Annual Report 2010 on the State of the Drug Problem in Europe; p. 92-93. 
14 See Annex (section 5) for an overview of these EU instruments. 
15 Some new psychoactive substances can be treated as food, since any substance meant to be ingested 
orally is considered to be food and subject to food safety legislation (Article 2 of Regulation (EC) No 
178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general 
principles and requirements of food law, establishing the European Food Safety Authority and laying 
down procedures in matters of food safety). 
16 Possession for personal use is not a criminal offence under medicines legislation, but is often so under 
drug control laws. Food safety and consumer protection legislation requires producers to prove the 
safety of their products. 
17 Mephedrone, which was submitted to control measures across the EU on 2 December 2010 (OJ L 322, 
20.12.2010, p. 44), was marketed as ‘plant food’, other products are e.g. sold as 'bath salts' or 'room 
odorisers'. 
18 These articles deal with police and judicial cooperation in criminal matters and the adoption of 
measures establishing minimum rules relating to the constituent elements of criminal acts and to 
penalties in the field of illicit drug trafficking. The Lisbon Treaty challenges the legal rationale of the 
Council Decision as it repealed ex-Article 34(2)(c) TEU, on the basis of which the decision to submit a 
substance to control measures could be taken. The decision to submit mephedrone to control measures 
could only be taken pursuant to the principle of preservation of the third pillar acquis. 
19 1-Benzylpiperazine. 
20 4-methylmethcathinone. 
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The scope of the Council Decision is defined by analogy with that of the drug control system 
as foreseen in the UN Conventions on drugs, which it seeks to reproduce at EU level.21 It 
covers substances that are not scheduled under these Conventions and which may pose a 
comparable threat to public health. It does not cover drugs precursors22 or substances that are 
used in the manufacturing of medicinal products23. The Council Decision does not intend to 
replace Member States’ legislation on new psychoactive substances, but rather to address 
those substances that are, or could become, a problem across the EU.  
4. FUNCTIONING OF THE COUNCIL DECISION  
A record number of new substances (41) were reported in 2010, more than a third of all 
substances notified since 2005. This increase in the number of notifications illustrates not 
only the rapid rise in the number of substances available in the EU but also improved 
reporting capacities in some Member States. Five countries accounted for 75 % of all first 
notifications, with the UK reporting one third of new substances, which reflects the UK's high 
level reporting and identification capabilities.24 
Since not all Member States adopt a proactive approach (through controlled test purchases on 
the internet and from specialised shops) the number of new substances on the market may be 
higher than reported.  
Until now notifications from Member States have led to the publication of three Joint Reports: 
on mCPP25 (2006), BZP (2007) and mephedrone (2010). The Joint Reports on BZP and 
mephedrone were followed by risk assessment.26  
The risk assessments on BZP and mephedrone provided arguments for submitting the 
substances to control measures. Both concluded that the substances posed risks for health and 
society but acknowledged that there was limited scientific evidence on the acute and long-
term effects on health and fatalities, on consumption patterns and on prevalence.  
The Council Decision stipulates that, based on the findings of the risk assessment, the Council 
may decide on the submission of the substance to control measures and on the obligation to 
introduce criminal law measures. The lack of alternatives (i.e. measures other than criminal 
ones) mirrors the mechanism of the UN Conventions on illicit drugs. In both cases (BZP and 
mephedrone) when a substance was assessed, the Commission proposed — and the Council 
                                                 
21 Article 3(b) and (c). 
22 Chemicals used to manufacture drugs. 
23 Article 7(3). 
24 See Annex (section 4). 
25 1-(3-chlorophenyl) piperazine. 
26 mCPP was not assessed because the substance is used in the manufacture of medicinal products. It 
could not be followed up under the pharmacovigilance system either. The Council Decision does not 
foresee monitoring of substances not submitted to risk assessment, but reports from third sources 
indicate that mCPP continued to be present in the market, as such or in ecstasy tablets. The 
pharmacovigilance system is the process of monitoring the safety of medicines and taking action to 
reduce their risks and increase their benefits. Regulation (EC) No 726/2004 of the European Parliament 
and of the Council of 31 March 2004 laying down Community procedures for the authorisation and 
supervision of medicinal products for human and veterinary use and establishing a European Medicines 
Agency. OJ L 136, 30.4.2004, p. 1-32. 
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agreed27 — to submit it to control measures, requiring Member States to introduce criminal 
sanctions28. In the case of BZP, the Council Decision29 acknowledged that the risk assessment 
lacked conclusive evidence on the overall risks of the substance but it stated ‘following the 
precautionary principle’ that it was necessary to take measures because of its risk to health. 
5. RESULTS OF THE SURVEY 
The survey conducted among the Member States30 shows that the information exchange 
mechanism is a useful tool for alerting them to new substances detected in neighbouring 
countries. However, a number of countries point out that additional information should be 
provided, in particular toxicology or forensic information. Most Member States indicate that 
substances that are not submitted to risk assessment following a Joint Report should 
nevertheless be actively monitored. 
While the Scientific Committee acknowledges that risk assessments are inherently based on 
partial knowledge, given the scarcity of information on these new substances, it points out 
that additional resources should be made available to support the risk assessment process, for 
instance for conducting toxicology tests. Several Member States back this view. 
Numerous Member States are concerned that the Council Decision can only address one 
psychoactive substance at a time. They argue that this approach prevents a comprehensive 
response, because as soon as a substance is submitted to control measures, a new one may be 
developed and easily marketed to replace it. It also makes it difficult to take action on drugs 
that are composed of several substances, in various combinations, each of which should be 
studied individually. This is why no action was taken at EU level on Spice.  
A number of Member States have tried addressing several substances at a time, adopting a 
generic approach,31 but not all Member States use this method. While simultaneous control 
measures for a group of chemically related substances is one way of dealing with the problem 
which deserves a thorough discussion, to assess different substances simultaneously is 
difficult in practice and scientifically less robust, as the effects and potential harm vary widely 
between substances included in any generic group. The Scientific Committee of EMCDDA 
indicated that a broader discussion on chemically similar compounds could be included in risk 
assessments to provide better insights into related substances that could be launched in the 
market.  
The survey showed that a large number of Member States see the current lack of alternatives 
to criminal control as inadequate and point out that a wider range of options should be 
considered, in particular temporary control and risk management measures.  
As far as the timing for decision-making is concerned, all the Member States stress that swift 
action is necessary to tackle new psychoactive substances. According to the survey the 
majority of Member States believe that the decision-making process is too slow: BZP was 
                                                 
27 Member States must take national measures to implement, within one year, Council decisions to this 
effect (Article 9(1)). 
28 COM (2007) 430 final, 17.7.2007; COM (2010) 583 final; 2010/0293 (NLE), 20.10.2010. 
29 OJ L 63, 7.3.2008, p.45 — recital 8. 
30 See Annex (section 7) for a summary report of the findings of the survey. 
31 Simultaneous assessment and/or control of a group of chemically-related compounds. 
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submitted to control 15 months after the launch of the Joint Report, and mephedrone 12 
months after. 
Seventeen Member States would be in favour of a fast-track/emergency procedure, in 
particular when a substance is raising considerable concern and more time is required for 
conducting further scientific research. Certain Member States already use this emergency 
approach — an accelerated procedure to restrict the sale of new substances for a limited 
period of time. One Member State suggested that a standing committee could be set up so that 
EU institutions and agencies can decide on temporary measures. Another Member State 
recommended caution with respect to emergency measures, pointing to the risk that the ban 
might not be lifted, even if the risk assessment fails to provide evidence of the harms caused 
by a substance. 
6. NEED FOR A COMPREHENSIVE APPROACH 
Although the public threat from new psychoactive substances might appear to be lower than 
that of traditional illicit drugs,32 the duty to protect public health leaves no room for 
complacency. Therefore, a firm and comprehensive response should be developed at EU level 
to the frequent emergence and rising popularity of these substances. The key challenge is that 
they are manufactured and traded in a regulatory grey area, somewhere between drugs 
control, food safety, consumer protection, medicines and chemicals legislation. Authorities in 
many Member States are often unsure what legislation would tackle these substances most 
effectively.  
The Council Decision may be regarded both as a tool designed to protect public health as well 
as a criminal justice instrument, aimed at addressing new psychoactive substances through 
enhanced law enforcement and judicial cooperation among the Member States. Nevertheless, 
it has been extensively applied over the past five years, mostly as a public health tool, 
enabling authorities to exchange information about new substances and to understand and 
anticipate trends in this rapidly changing market. It has been used as a criminal justice 
instrument only twice: to submit two substances to control measures and subsequently to 
criminal sanctions.  
Many substances that were notified by the Member States were not of EU-wide concern and 
were therefore dealt with at national level. Certain products, for instance Spice, raised 
concerns across several EU Member States, but were not dealt with at EU level because of the 
limited scope for action under the Council Decision to address such mixtures of substances. 
Several other substances that have raised public health concerns could probably have been 
tackled at EU level had the Council Decision offered ‘lighter’ risk-management options, in 
addition to criminal control measures.  
Mirroring the UN Conventions on drugs, the scope of the current Council Decision limits the 
options for addressing these substances, thus reducing the number of substances that can 
effectively be tackled at EU level. Although there seems to be a consensus among Member 
                                                 
32 The risk assessment reports on BZP and mephedrone identified two deaths in which these substances 
appeared to be the sole cause of death, although in the meantime more cases were confirmed. The 
EMCDDA estimates that 7,500 to 8,000 individuals die every year in the EU as a result of opiate and 
cocaine overdose. 10458/07, CORDROGUE 35, 5.6.2007; 12658/10, CORDROGUE 67, 29.7.2010. 
EMCDDA 2010 Annual Report on the State of the Drug Problem in Europe, p.16. 
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States that criminal law should be part of the answer to new psychoactive substances at EU 
level, most seem to agree that it is not always a sustainable option for tackling the spread of 
new psychoactive substances and at any rate should not be the only option. Member States 
agree that the ultimate goal of control is to protect citizens from the unknown risks 
surrounding these substances.  
The information exchange and risk assessment phases allowed Member States to swap 
information and provided them with relevant and timely feedback on trends and developments 
in this rapidly evolving market. Risk assessment provides an indispensable pooling of EU-
wide research, but it needs to be stepped up, so that decisions are based on evidence. 
According to the Survey, in order to address the inherent constraints of assessing new 
substances on which there is little information, resources should be made available, in 
particular to support toxicology, forensic analysis and pharmacological studies.  
On the question of decision-making, the Survey makes it clear that a rapid EU response is 
crucial. According to some Member States quicker action could be taken using instruments 
that work well in the fields of food and product safety and of dangerous chemicals. In some 
cases these could be intermediary steps, pending a decision on criminal control measures. 
These systems have a notification and information exchange mechanism, as well as 
emergency procedures in the event of imminent health threats (including temporary bans). 
They also have classification systems that enable authorities to act proportionately to the risk 
of the product assessed. Such mechanisms could give the Member States greater flexibility 
when deciding on the most appropriate way to tackle specific substances while enabling them 
to act faster.  
7. CONCLUSIONS — THE WAY FORWARD 
The Council Decision on new psychoactive substances is certainly a useful instrument for 
tackling new substances at the EU level, in particular as it allows for an exchange of 
information among the Member States (early warning system). However, it appears from this 
assessment that it has three major shortcomings when it comes to submitting these substances 
to Europe-wide control measures: 
• It is not able to tackle the large increase in the number of new psychoactive 
substances on the market, because it addresses substances one by one, through a 
lengthy process. 
• It is reactive, as substances submitted to control measures are quickly replaced with 
new ones with similar effects, often through small modifications of their chemical 
composition.  
• It lacks options for control measures. 
Therefore, subject to a further Impact Assessment, the Commission will examine the need for 
a more effective legal instrument. It will examine how to reconcile the need for a rapid 
response with enhanced risk assessment of substances. It will assess measures to extend the 
support for collecting toxicological and forensic information. 
The Commission sees the need for a comprehensive response at EU level, closing gaps 
between drugs control and other types of legislation, including food or product safety. In 
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addition to criminal justice control measures, alternative risk management options would need 
to be assessed with a view to a faster response, at EU level, to the emergence of substances 
that raise concerns.  
To improve understanding of the rapidly evolving market for new psychoactive substances, 
the Commission will examine ways of monitoring substances that are not submitted to risk 
assessment but that cause concern33 as well as those subjected to control measures.  
Any legislative proposals on new psychoactive substances should be based on thorough and 
comprehensive analysis and debate. Therefore, the European Parliament and the Council are 
invited to take part in the debate on how EU legislation in this field could be made more 
effective. In the autumn, the Commission intends to present to the European Parliament and 
the Council, the main objectives and options for revising Council Decision 2005/387/JHA.  
As legislation alone will not provide the complete answer to the complex challenge posed by 
new psychoactive substances, the Commission invites Member States to step up their efforts 
to improve the efficiency of drug information and prevention programmes,34 which should 
take into account the rising popularity of new psychoactive substances.  
                                                 
33 E.g. mCPP and SPICE. 
34 The development of integrated and innovative approaches to identify, monitor and respond to trends in 
the consumption of new psychoactive substances is a priority under the Commission’s Drug Prevention 
and Information Programme. Decision No 1150/2007/EC of the European Parliament and of the 
Council of 25 September 2007 establishing for the period 2007-2013 the Specific Programme ‘Drug 
prevention and information’ as part of the General Programme 'Fundamental Rights and Justice'; OJ L 
257, 03.10.2007, p. 23. 
